Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours

Lancet. 1984 Mar 3;1(8375):484-6. doi: 10.1016/s0140-6736(84)92852-6.

Abstract

NMR imaging was performed on 12 patients with cerebral tumour before and after administration of intravenous gadolinium diethylene triamine penta-acetic acid (DTPA) (0.1 mmol/kg). Contrast enhancement was seen in all cases. Ring enhancement was most frequent (7 cases) but central, linear, patchy, and diffuse enhancement were also seen with both inversion-recovery and spin-echo sequences. The degree of enhancement was greater than that seen with X-ray computed tomography (CT) in 8 cases, equal to it in 3 cases, and less in 1 case. NMR distinguished between tumour and peritumoral oedema to the same extent as did CT. No side-effects were encountered and there was no significant change in urea, creatinine and electrolytes, liver function tests, blood coagulation, or urine testing after administration of gadolinium-DTPA. Gadolinium-DTPA is likely to be of considerable value in NMR imaging of the brain.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Brain Edema / diagnosis
  • Brain Edema / diagnostic imaging
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / diagnostic imaging
  • Contrast Media / administration & dosage
  • Evaluation Studies as Topic
  • Female
  • Gadolinium* / administration & dosage
  • Gadolinium* / urine
  • Humans
  • Injections, Intravenous
  • Magnetic Resonance Spectroscopy* / methods
  • Male
  • Middle Aged
  • Pentetic Acid* / administration & dosage
  • Pentetic Acid* / urine
  • Radiographic Image Enhancement
  • Tomography, X-Ray Computed

Substances

  • Contrast Media
  • Pentetic Acid
  • Gadolinium